Education
About Us
Working with TipRanks
Follow Us
Jason Alan Carroll Insider Profile
4 Followers
Jason Alan Carroll, Chief Executive Officer at Tryptamine Therapeutics, holds 56.80M shares in Tryptamine Therapeutics (Ticker: AU:ENP), holds 32.07M shares in Island Pharmaceuticals Ltd (Ticker: AU:ILA). Most recently, Jason Alan Carroll Bought ― shares of Tryptamine Therapeutics on Mar 10, 2026 for an estimated value of AU$75.00K.
Jason Alan Carroll Tryptamine Therapeutics (ENP)Chief Executive Officer
Tryptamine Therapeutics (ENP)
Chief Executive Officer
Ranked #10,680 out of 106,487 Corporate Insiders
Profitable Transactions
4 out of 4 Profitable Transactions
Average Return
+54.70%
Average return per transaction
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Jason Alan Carroll holds in companies
Most Profitable Insider Trade
Stock:
Rating:Informative Buy
Date:Jul 25, 2025 - Today
Return:+200.00%
The most profitable trade made by Jason Alan Carroll
Jason Alan Carroll's Trading History
Tryptamine Therapeutics
Mar 10, 2026
Chief Executive Officer
Informative Buy
75.00K
AU$1.76M
Island Pharmaceuticals Ltd
Dec 03, 2025
Director, Ten Percent Owner
Uninformative Sell
68.25K
AU$12.83M
List of latest transactions for each holding click on a transaction to see Jason Alan Carroll's performance on stock
You May Also Like
Jason Alan Carroll insider profile FAQ
What is the percentage of profitable transactions made by Jason Alan Carroll?
The percentage of profitable transactions made by Jason Alan Carroll is 100%.
What is the average return per transaction made by Jason Alan Carroll?
The average return per transaction made by Jason Alan Carroll is 54.70%.
What stocks does Jason Alan Carroll hold?
Jason Alan Carroll holds: AU:ENP, AU:ILA stocks.
What was Jason Alan Carroll’s latest transaction?
Jason Alan Carroll latest transaction was an Informative Buy of AU$75.00K.
What was Jason Alan Carroll's most profitable transaction?
Jason Alan Carroll’s most profitable transaction was an Informative Buy of AU:ILA stock on July 25, 2025. The return on the trade was 200.00%.
What is Jason Alan Carroll's role in Tryptamine Therapeutics?
Jason Alan Carroll's role in Tryptamine Therapeutics is Chief Executive Officer.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.